Da	te:2023/04/2	5	
Yo	ur Name:Cheng-Har	ı Wu	
Ma	nuscript Title: Feas	ibility Evaluation of Middle-	Phase 18F-florbetaben Positron Emission Tomography Imaging
Usi	ing Centiloid Quantific	ation and Visual Assessmer	nt
Ma	nuscript number (if kr	nown):	
related to the mass of the mas	ated to the content of rties whose interests no transparency and does ationship/activity/interests of the following questions and the epidemiology of he dication, even if that in the selection of the following even if that in the selection of the following even if that in the selection of the following even if that in the selection of the following even if that in the selection of the selection	your manuscript. "Related' may be affected by the cont is not necessarily indicate a erest, it is preferable that you apply to the author's relation os/activities/interests shoul ypertension, you should de medication is not mentione	onships/activities/interests as they relate to the <u>current</u> d be <u>defined broadly</u> . For example, if your manuscript pertains clare all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this relationship or indicat none (add rows as needed)	(e.g., if payments were made to you or to your
		-	initial planning of the work
	All support for the prese		initial planning of the work
•	manuscript (e.g., funding provision of study mate medical writing, article processing charges, etc. No time limit for this it.	ng, erials, er	
2	Grants or contracts from any entity (if not indication item #1 above).	m _XNone ted	past 36 months
3	Royalties or licenses	XNone	
1	Consulting fees	X None	

5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	XNone	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
ni.	noco cummorino the chouse	andlist of interest in the	Allowing how
PIE	ease summarize the above o	——————————————————————————————————————	Dilowing Dox:
	None.		

Da	te:	_2023/04/25			_
Yo	ur Name:_	_ Yueh-Hsun Lu _			
Usi	ing Centilo	id Quantification	Evaluation of Middle-Pha and Visual Assessment :	se 18F-florbetaben Positron Emission Tomography Imag	¦ing
rela par to	ated to the rties whose transparer	e content of your e interests may bo ncy and does not i	manuscript. "Related" me e affected by the content	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.	
	e following anuscript o		to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>	
to	the epiden	niology of hyperto		e <u>defined broadly</u> . For example, if your manuscript perta e all relationships with manufacturers of antihypertension the manuscript.	
			oport for the work reporte s the past 36 months.	ed in this manuscript without time limit. For all other ite	ems,
			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initia	al planning of the work	
L	manuscrip provision of medical with processing	t for the present t (e.g., funding, of study materials, riting, article charges, etc.) mit for this item.	XNone		
			Time frame: pas	t 36 months	
)	any entity	contracts from (if not indicated	_XNone	r so monais	
2	in item #1 Royalties o	·	Y None		
,	Noyalties C	n nicerises	XNone		

Consulting fees

X__None

5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	XNone	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
ni.	noco cummorino the chouse	andlist of interest in the	Allowing how
PIE	ease summarize the above o	——————————————————————————————————————	Dilowing Dox:
	None.		

Da	te:2023/04/25		
Yo	ur Name: Tse-Hao Lee		
			se 18F-florbetaben Positron Emission Tomography Imaging
		n and Visual Assessment	
Ma	anuscript number (if know	า):	
related to the mean of the to the mean of the to th	ated to the content of you rties whose interests may large transparency and does not ationship/activity/interest e following questions applanuscript only. e author's relationships/activity epidemiology of hyperedication, even if that medication in the content of the epidemiology of the epidemiology of hyperedication, even if that medication, even if that medication.	r manuscript. "Related" me be affected by the content c necessarily indicate a bias , it is preferable that you d y to the author's relationsh ctivities/interests should be tension, you should declar ication is not mentioned in	nips/activities/interests as they relate to the <u>current</u> e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as needed)	
		Time frame: Since the initial	al planning of the work
1	All support for the present	X None	an premium g or time trom
	manuscript (e.g., funding,	<u>XNone</u>	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	at 36 months
2	Grants or contracts from	_XNone	
	any entity (if not indicated		
	in item #1 above).	_	
3	Royalties or licenses	XNone	
1 I	Consulting fees	X None	

5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	XNone	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
ni.	noco cummorino the chouse	andlist of interest in the	Allowing how
PIE	ease summarize the above o	——————————————————————————————————————	Dilowing Dox:
	None.		

Da	te:2023/04/25						
	ur Name: Chun-Yuan Tu _						
Ma	nuscript Title: Feasibility	Evaluation of Middle-Pha	se 18F-florbetaben Positron Emission Tomography Imaging	,			
Usi	Jsing Centiloid Quantification and Visual Assessment						
Ma	nuscript number (if known)):					
rel pa to rel	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest,	manuscript. "Related" me e affected by the content necessarily indicate a bias it is preferable that you d	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment if I you are in doubt about whether to list a o so. hips/activities/interests as they relate to the current				
to me	the epidemiology of hypertedication, even if that medic	ension, you should declard ation is not mentioned in pport for the work reporte	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript. ed in this manuscript without time limit. For all other items	5,			
		T					
		Name all entities with	Specifications/Comments				
		whom you have this	(e.g., if payments were made to you or to your				
		relationship or indicate none (add rows as	institution)				
		needed)					
		Time frame: Since the initia	al planning of the work				
1	All support for the present	X None					
L	manuscript (e.g., funding,						
	provision of study materials,						
	medical writing, article						
	processing charges, etc.)						
	No time limit for this item.						
	to time initial to this item.						
		T: 6	4.2C was what				
,	Cuanta au santua sta fue	Time frame: pas	t 56 months				
<u>*</u>	Grants or contracts from	_XNone					
	any entity (if not indicated in item #1 above).						
	m nem #1 above).	i					

Royalties or licenses

Consulting fees

_X__None

_X__None

5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	XNone	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
ni.	noco cummorino the chouse	andlist of interest in the	Allowing how
PIE	ease summarize the above o	——————————————————————————————————————	Dilowing Dox:
	None.		

Da	te:2023/04/25							
	ur Name: Jong-Ling Fuh _							
Us	Manuscript Title: Feasibility Evaluation of Middle-Phase 18F-florbetaben Positron Emission Tomography Imaging Using Centiloid Quantification and Visual Assessment Manuscript number (if known):							
rel pa to	ated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.					
	e following questions apply inuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>					
to		ension, you should declare	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.					
	item #1 below, report all sup e time frame for disclosure is		ed in this manuscript without time limit. For all other items					
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)					
		Time frame: Since the initia	al planning of the work					
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone						
		Time frame: pas	t 36 months					
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone						
3	Royalties or licenses	X_None						

Consulting fees

X__None

5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	XNone	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
ni.	noco cummorino the chouse	andlist of interest in the	Allowing how
PIE	ease summarize the above o	——————————————————————————————————————	Dilowing Dox:
	None.		

Da	ite:2023/04/25		
	our Name: Yuh-Feng Wang		
M	anuscript Title: Feasibility	Evaluation of Middle-Pha	ase 18F-florbetaben Positron Emission Tomography Imaging
Us	ing Centiloid Quantification	and Visual Assessment	
	anuscript number (if known)		
re pa to	lated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content necessarily indicate a bias	Ill relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a lo so.
	e following questions apply anuscript only.	to the author's relationsh	nips/activities/interests as they relate to the <u>current</u>
to m	the epidemiology of hypertoedication, even if that medic	ension, you should declar cation is not mentioned in	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript. ed in this manuscript without time limit. For all other items
th	e time frame for disclosure i	s the past 36 months.	
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initi	al planning of the work
	All support for the present	X None	
	manuscript (e.g., funding,	XNOTIE	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	st 36 months
	Grants or contracts from	X None	of the months
	any entity (if not indicated	NOTIC	
	in item #1 above).		
	Royalties or licenses	X None	
	Noyalties of licelises	^NOTIE	
	Consulting fees	X None	

5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	XNone	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
ni.	noco cummorino the chouse	andlist of interest in the	Allowing how
PIE	ease summarize the above o	——————————————————————————————————————	Dilowing Dox:
	None.		

Dat	e:	2023/04/25		
		Bang-Hung Yang		
Maı	nuscript Ti	tle: Feasibility	Evaluation of Middle-Phas	se 18F-florbetaben Positron Emission Tomography Imaging
Usir	ng Centiloi	d Quantification	and Visual Assessment	
Maı	nuscript nu	umber (if known)	:	
rela part to t rela The mar The to t med	ted to the ties whose ransparentionship/a following nuscript or author's rate epidem dication, even #1 belowers	content of your interests may be cy and does not a activity/interest, questions apply aly. relationships/activiology of hypertoven if that medic ow, report all support and activity and activity are supported to the content of the	manuscript. "Related" mede affected by the content of necessarily indicate a bias. It is preferable that you do to the author's relationship ivities/interests should be ension, you should declare ation is not mentioned in the safety of the	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
			Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
			relationship or indicate none (add rows as needed)	institution)
			Time frame: Since the initia	I planning of the work
	All support	for the present	X None	Therming of the World
	manuscript provision o medical wr processing	f (e.g., funding, f study materials, iting, article charges, etc.) nit for this item.		
			-:	2C
	Grants or o	ontracts from	Time frame: past X None	36 Months
		if not indicated	NOTIC	
	Royalties o	<u> </u>	XNone	
	Consulting	fees	XNone	

5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	-		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Receipt of equipment,	_XNone	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	X None	
13	financial interests	_XNone	
	illiancial interests		
Ple	ease summarize the above o	onflict of interest in the f	ollowing box:
Г	None.		
	•		